机构:[1]Department of Medical Oncology, Zengcheng District People’s Hospital of Guangzhou, Guangzhou, China[2]Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, Guangzhou, China临床科室临床研究部/药物临床试验机构中山大学肿瘤防治中心[3]Department of Medical Oncology, Ganzhou People’s Hospital, Jiangxi province, China[4]Experimental Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China临床科室其他部门临床研究部/药物临床试验机构华南肿瘤学国家重点实验室中山大学肿瘤防治中心[5]Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[6]Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
Abstract: STING and MIF are Tumor-immune related proteins act as immune regulating roles that effect the progression of cancer. In these studies, we aimed to detect the expression levels of STING and MIF in tumor cells and in lymphocytes in tumor microenvironments and their association with survivals of patients diagnosed with esophageal squamous cell carcinoma (ESCC). The expression levels of STING and MIF were accessed by immunochemistry staining in tumor tissues from 112 resected ESCC. Correlation analyses and independent prognostic outcomes were determined using Pearson's chi-square test. Independent prognostic outcomes were measured by Cox regression analysis. We found that STING high expression in TILs or MIF high expression in tumor cells or in tumor infiltrating lymphocytes (TILs) was significantly related to reduced disease-free survival (DFS) and overall survival (OS) of ESCC patients (P<0.05). Multivariate analysis indicated that the expression of STING and MIF in TILs were adverse independent prognostic factors in the whole cohort of patients (P<0.05). The expression of MIF in tumor cells or in TILs was significantly positively correlated with STING in TILs (P<0.05). The combined STING and MIF expression in TILs was strongly related to reduced DFS and OS of ESCC patients (P<0.05). Our studies indicated the expression levels of STING and MIF in TILs were independent predictive factors of survivals in patients with ESCC.
基金:
Guangdong Eso-phageal Cancer Research Institute Project [Q201405]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|4 区医学
小类|4 区肿瘤学4 区病理学
最新[2023]版:
无
第一作者:
第一作者机构:[1]Department of Medical Oncology, Zengcheng District People’s Hospital of Guangzhou, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Medical Oncology, Zengcheng District People’s Hospital of Guangzhou, Guangzhou, China[4]Experimental Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China[5]Collaborative Innovation Center for Cancer Medicine, Guangzhou, China[6]Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China[*1]Department of Medical Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou 510120, Guangdong Province, China.[*2]Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou 510060, China.
推荐引用方式(GB/T 7714):
Wang Zhi-Chao,Zhang Lin,Li Ze-Lei,et al.Expression of STING and MIF in tumor infiltration lymphocytes as prognostic factors in patients with ESCC[J].International journal of clinical and experimental pathology.2017,10(9):10066-+.
APA:
Wang, Zhi-Chao,Zhang, Lin,Li, Ze-Lei,He, Jing,Cai, Ting-Ting...&Xie, De-Rong.(2017).Expression of STING and MIF in tumor infiltration lymphocytes as prognostic factors in patients with ESCC.International journal of clinical and experimental pathology,10,(9)
MLA:
Wang, Zhi-Chao,et al."Expression of STING and MIF in tumor infiltration lymphocytes as prognostic factors in patients with ESCC".International journal of clinical and experimental pathology 10..9(2017):10066-+